Business Context and Reporting Period
Capstone Therapeutics Corp. (formerly OrthoLogic Corp.; the filing does not identify the registrant as Capstone Holding Corp.) filed its Form 10-K for the fiscal year ended December 31, 2011, signed March 21, 2012. The company was a development-stage biotechnology business focused primarily on AZX100 and Chrysalin (TP508), with no FDA-approved products and no revenue-generating operations.
During 2011, the company completed its Phase 2 AZX100 dermal-scarring study following shoulder surgery. On October 13, 2011, it reduced staffing from 18 employees to four to preserve cash. In January 2012, management announced plans to cease AZX100 clinical development, discontinue TP508 activities, return TP508 intellectual property to the University of Texas, and move toward winding down operations while pursuing partnering or strategic transactions.
Financial Results and Key Metrics
| Metric | 2011 | 2010 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No product revenue |
| General and administrative expense | $3.506 million | $3.240 million | Up 8.2% |
| Research and development expense | $6.394 million | $8.168 million | Down 21.7% |
| Total operating expenses | $9.900 million | $11.408 million | Down 13.2% |
| Interest and other income, net | $31 thousand | $356 thousand | Down 91.3% |
| Net loss | $9.711 million | $10.871 million | Loss narrowed 10.7% |
| Basic and diluted loss per share | $0.24 | $0.27 | Improved |
| Cash used in operating activities | $10.590 million | $10.695 million | Down 1.0% |
| Cash and cash equivalents | $13.778 million | $24.387 million | Down 43.5% |
| Working capital | $14.417 million | $23.214 million | Down 37.9% |
| Total assets | $14.696 million | $25.288 million | Down 41.9% |
| Stockholders’ equity | $14.577 million | $7.916 million | Up primarily from expiration of put-right accounting |
Margins are not meaningful because the company had no revenue. The filing does not identify material debt; reported liabilities were $119 thousand at December 31, 2011, consisting primarily of accounts payable and accrued liabilities. The company had approximately $134 million of federal and $56 million of state net operating loss carryforwards, but recorded a full valuation allowance of approximately $55 million against deferred tax assets.
Material Changes Versus the Prior Comparable Period
- R&D expense declined as AZX100 Phase 2 clinical activity wound down; the decrease was partly offset by approximately $600 thousand of severance-related R&D costs.
- G&A expense increased despite reduced activity because approximately $1.1 million of severance was recorded following staff and executive reductions.
- Total severance payments related to employment and compensation changes were approximately $1.7 million, most of which occurred in the fourth quarter.
- Net loss narrowed by approximately $1.2 million, primarily because of lower clinical costs and reduced operating activity.
- Cash declined by approximately $10.6 million during 2011, principally reflecting operating cash burn.
- Put rights expired on June 30, 2011. The related $15.556 million potentially redeemable equity balance was removed and reclassified within stockholders’ equity; this was an accounting change, not operating cash generation.
- The company’s common stock was delisted from Nasdaq in July 2011 and traded on the OTCQB thereafter.
Outlook, Risks, Contingencies, and Unusual Items
- Management estimated 2012 cash expenditures of $2.5 million to $3.0 million if the wind-down plan continued, excluding potentially significant qui tam litigation costs.
- Management expected cash and short-term investments at December 31, 2011 to fund presently projected requirements for the following year, but additional capital would be required to resume clinical development and pursue FDA approval.
- The independent auditor reported substantial doubt about the company’s ability to continue as a going concern, citing uncertainty regarding future business strategy. The financial statements contain no going-concern adjustments.
- The company is defending a qui tam Federal False Claims Act lawsuit related to its former bone-growth-stimulation-device business. The government declined to intervene, the motion to dismiss was denied, discovery was open, and no trial date had been set. Claimed damages could exceed the company’s financial resources and could prevent continuation of the business.
- The company had no active clinical trials at December 31, 2011 and no products approved for marketing. Future value depended on AZX100 partnering or other strategic transactions, although clinical development was subsequently halted.
- Key risks included regulatory failure, unsuccessful clinical or preclinical results, inability to obtain financing or partners, intellectual-property challenges, competition, product liability, dependence on consultants and third-party manufacturers, litigation exposure, and potential dilution from equity awards and future financing.
- The filing states that the TP508 intellectual property was returned to the University of Texas effective March 1, 2012, after the January 2012 decision to discontinue TP508 development.
Most Important Facts for Investors to Verify
- Confirm the issuer identity: the supplied filing is for Capstone Therapeutics Corp., not Capstone Holding Corp.
- Verify the final status, estimated cost, and resolution of the qui tam litigation, including whether any reserve or settlement obligation was later recorded.
- Verify post-year-end cash balances, actual 2012 cash expenditures, and whether the wind-down, merger, liquidation, or partnering strategy was completed.
- Review subsequent filings for the cessation of AZX100 development and the effective return of TP508 intellectual property.
- Reconcile the substantial-doubt going-concern disclosure with later financing, strategic-transaction, or dissolution disclosures.
- Assess potential dilution from approximately 3.373 million outstanding options, 164,129 warrants, preferred-stock authorization, and any subsequent equity issuance.